Sino Biological Launches XPressMAX Cell-Free Protein Synthesis Kit for AI-Driven Antibody Discovery
核心洞察
Sino Biological (搜索) has launched the XPressMAX Cell-Free Protein Synthesis Kit (搜索), enabling ultra-fast protein and antibody synthesis in just 3 hours with a >99% success rate.
The kit leverages E. coli lysate-based cell-free technology to eliminate constraints of traditional cell-based expression systems and integrates seamlessly with AI-powered screening platforms.
The platform can validate over 2,000 scFv (搜索)/VHH (搜索) molecules in 3-4 weeks, matching the rapid iteration demands of AI-driven antibody drug discovery.
Sino Biological (搜索), Inc. (Shenzhen Stock Exchange: 301047.SZ) has announced the launch of its XPressMAX Cell-Free Protein Synthesis Kit (搜索) (Cat#: CFKIT02), a breakthrough technology designed to accelerate artificial intelligence-driven high-throughput screening for antibody drug discovery. The innovative kit enables ultra-fast protein and antibody synthesis in just 3 hours, addressing the speed demands of modern AI-powered drug development pipelines.
Revolutionary Cell-Free Technology
The XPressMAX kit leverages advanced cell-free protein synthesis technology to enable rapid, efficient in vitro production of target proteins and antibodies, eliminating the constraints of traditional cell-based expression systems. Based on an E. coli lysate and fully supplemented with essential transcription and translation components, the system enables direct protein synthesis from plasmid or PCR templates.
The technology demonstrates remarkable performance metrics, achieving a success rate greater than 99% while supporting complex disulfide bonding and native protein folding without requiring additional enhancers. This capability is particularly significant for antibody drug discovery applications, where proper protein folding is critical for bioactivity.
High-Throughput Platform Integration
Specifically designed for antibody drug discovery, XPressMAX enables rapid expression and validation of various antibody formats including VHH (搜索), scFv (搜索), Fab (搜索), and miniproteins. Sino Biological (搜索) has established a high-throughput cell-free expression platform leveraging this technology that can validate over 2,000 scFv/VHH molecules in 3-4 weeks, matching the rapid iteration demands of AI-powered screening systems.
"AI is revolutionizing antibody screening, but it demands expression systems that can match its speed and throughput," said Dr. Jie Zhang, Sino Biological (搜索)'s General Manager. "XPressMAX achieves rapid, high-success expression of challenging proteins in as little as 3 hours."
Industry Impact and Applications
The launch represents a significant advancement in research tools for next-generation therapeutic discovery. By seamlessly integrating with AI-powered screening platforms, the kit empowers researchers to dramatically accelerate the identification and optimization of promising antibody candidates while reducing both development timelines and costs.
"Our XPressMAX is a significant advancement in research tools and reagents for next-generation therapeutic discovery," said Dr. Rob Burgess, Chief Business Officer at Sino Biological (搜索) US, Inc. "By combining rapid, reliable protein expression with intelligent screening, we are helping our partners compress antibody discovery timelines without compromising quality."
Company Background
Sino Biological (搜索) operates as an international reagent supplier and contract research organization specializing in recombinant protein production and antibody development. The company serves researchers in over 90 countries and maintains facilities including the US-based Center for Bioprocessing in Houston and SignalChem Biotech in Canada, delivering tailored solutions to meet diverse research needs worldwide.